American Renal Associates Holdings Inc (NYSE:ARA) – Stock analysts at SunTrust Banks dropped their Q1 2018 earnings estimates for shares of American Renal Associates in a note issued to investors on Wednesday, Zacks Investment Research reports. SunTrust Banks analyst D. Macdonald now anticipates that the company will post earnings per share of $0.09 for the quarter, down from their previous forecast of $0.10. SunTrust Banks has a “Buy” rating and a $20.00 price target on the stock. SunTrust Banks also issued estimates for American Renal Associates’ Q2 2018 earnings at $0.16 EPS, Q3 2018 earnings at $0.17 EPS, Q4 2018 earnings at $0.19 EPS, FY2018 earnings at $0.62 EPS, Q1 2019 earnings at $0.10 EPS, Q2 2019 earnings at $0.17 EPS, Q3 2019 earnings at $0.19 EPS, Q4 2019 earnings at $0.20 EPS and FY2019 earnings at $0.66 EPS.
Other analysts also recently issued research reports about the stock. Zacks Investment Research upgraded shares of American Renal Associates from a “sell” rating to a “hold” rating in a report on Tuesday, February 20th. Leerink Swann downgraded shares of American Renal Associates from an “outperform” rating to a “market perform” rating and raised their price objective for the stock from $17.00 to $27.00 in a report on Thursday, March 8th.
Shares of ARA stock traded down $0.74 on Friday, hitting $18.11. The stock had a trading volume of 242,250 shares, compared to its average volume of 164,712. American Renal Associates has a 12-month low of $9.91 and a 12-month high of $24.07. The company has a debt-to-equity ratio of 4.28, a current ratio of 1.20 and a quick ratio of 1.17. The company has a market cap of $593.03, a P/E ratio of 30.24, a P/E/G ratio of 1.30 and a beta of 1.92.
American Renal Associates (NYSE:ARA) last announced its earnings results on Tuesday, March 6th. The company reported $0.18 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.03. The company had revenue of $194.40 million during the quarter, compared to the consensus estimate of $195.15 million. American Renal Associates had a negative net margin of 1.00% and a positive return on equity of 14.51%. The firm’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.26 earnings per share.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. We Are One Seven LLC purchased a new stake in American Renal Associates during the fourth quarter worth about $131,000. The Manufacturers Life Insurance Company increased its holdings in American Renal Associates by 19.7% during the second quarter. The Manufacturers Life Insurance Company now owns 8,778 shares of the company’s stock worth $162,000 after buying an additional 1,443 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in American Renal Associates during the second quarter worth about $230,000. Citadel Advisors LLC purchased a new stake in American Renal Associates during the third quarter worth about $200,000. Finally, Alliancebernstein L.P. increased its holdings in American Renal Associates by 3.0% during the second quarter. Alliancebernstein L.P. now owns 13,900 shares of the company’s stock worth $258,000 after buying an additional 400 shares during the last quarter. Institutional investors and hedge funds own 91.64% of the company’s stock.
About American Renal Associates
American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.